# Ecnoglutide — dosage, half-life & reference guide | PepVault

Source: https://pepvault.app/peptides/ecnoglutide

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Metabolic & GLP-1](https://pepvault.app/peptides#metabolic)

# Ecnoglutide Dosage, half-life & reference guide

Also known as XW003 · XW004 · VRB-101 · Ecno

Reviewed November 2026 6 studies Evidence: Established [Published by PepVault](https://pepvault.app/guides/how-we-research)

A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". In its phase 3 obesity trial, the 2.4 mg dose took off about 13% at 40 weeks and about 15% at 48 weeks.

- **Studied range:** 0.6–2.4 mg starting dose 0.3 mg
- **How often:** Weekly
- **Half-life:** ~5.5 days
- **Evidence:** Established
- **Route:** SubQ injection

Studied in research — not a recommendation.

[Ecnoglutide dose guide](https://pepvault.app/lab/dosage/ecnoglutide)

## How it works.

Once-weekly GLP-1 receptor agonist, the same receptor as semaglutide, with one amino-acid change that is thought to favour the receptor's cAMP signal over the step that pulls the receptor into the cell, plus a fatty-acid chain for a long half-life. Developed by Sciwind Biosciences in China, where it was approved in 2026 for type 2 diabetes and for weight management; it is not FDA-approved. A weekly tablet form is in trials.

**Commonly reported:** Appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.

### Half-life & active level

The half-life of Ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).

Here's how a typical Ecnoglutide schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in [the half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator).

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track ecnoglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Where Ecnoglutide works.

- ### Appetite & metabolism

  **In people.** A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

## Week by week.

What to expect in the first 8 weeks

- **Onset:** Days–2 weeks
- **Peak effect:** 48 weeks (phase 3, no plateau)
- **Duration:** Ongoing

1. Day 1–28 · 0.3 mg RCT

   ### A low first month

   You're on 0.3 mg, the first step in ecnoglutide's diabetes trials. Commonly reported: appetite dropping within days. In those trials, GI side effects came mainly while the dose was stepping up and faded after.

   The science

   Phase 3 vs placebo in type 2 diabetes (Zhu 2026, Nat Commun; NCT05680155): "a slow dose-escalation regimen, starting at 0.3 mg ... with fixed double-dose increments every 4 weeks"; GI adverse events "mainly occurred in the dose escalation period and diminished over time".

   Sources

   - Zhu et al. (2026)

   Updated Nov 2026
2. Day 29–56 · 0.6 mg RCT

   ### Doubling to 0.6 mg

   You're at 0.6 mg, the second step, and one of the maintenance doses tested in type 2 diabetes. Commonly reported: a few queasy days after the step, then steadier appetite.

   The science

   In the type 2 diabetes trial, the 0.6 mg maintenance dose was reached at week 4 and 1.2 mg at week 8 (Zhu 2026). Pulse rose slightly on ecnoglutide, consistent with the GLP-1 class, and no severe hypoglycaemia was reported.

   Sources

   - Zhu et al. (2026)

   Updated Nov 2026
3. Any day RCT

   ### What Ecnoglutide is built on

   Phase 1 and 2 trials, a phase 3 obesity trial of 664 people, and two phase 3 diabetes trials, one against dulaglutide. China approved it in 2026. It is not FDA-approved.

   The science

   Discovery: a GLP-1 analogue with Val8 and a lysine-30 fatty acid, cAMP-biased with less receptor internalisation (Guo 2023, Mol Metab). SLIMMER (Ji 2025; NCT05813795, sponsor Hangzhou Sciwind Biosciences). Type 2 diabetes: vs placebo (Zhu 2026, Nat Commun) and vs dulaglutide (He 2025, Lancet Diabetes Endocrinol). Approvals: China, January 2026 (type 2 diabetes) and March 2026 (weight management) (Shirley 2026, Drugs). Interaction studies: Chen 2026 (warfarin, metformin), Li 2026 (rosuvastatin, digoxin).

   Sources

   - Guo et al. (2023)
   - Ji et al. (SLIMMER) (2025)
   - Zhu et al. (2026)
   - He et al. (2025)
   - Shirley (2026)

   Updated Nov 2026
4. With BPC-157 Community

   ### Why people add BPC-157 to a GLP-1

   GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.

   The science

   BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside ecnoglutide or any GLP-1 drug; the pairing comes from community reports.

   Sources

   - Sikiric et al. (2018)

   Updated Nov 2026

### After week 8

1. Day 57–336 · 1.2 mg RCT

   ### The lowest weight-loss dose

   You're at 1.2 mg, the lowest dose in the obesity trial. That group lost about 9% of body weight by week 40, and about three in four lost at least 5%.

   The science

   SLIMMER (Ji 2025, Lancet Diabetes Endocrinol; 664 adults without diabetes, 36 centres in China): 1.2 mg −9.1% at week 40 vs +0.1% on placebo (difference −9.2%); 77% reached ≥5% loss vs 16% (treatment-policy estimand).

   Sources

   - Ji et al. (SLIMMER) (2025)

   Updated Nov 2026
2. Day 85–336 · 1.8 mg RCT

   ### The middle dose

   You're at 1.8 mg. In SLIMMER, that group lost about 11% by week 40, and 84% lost at least 5%.

   The science

   SLIMMER week 40: 1.8 mg −10.9% vs +0.1% on placebo (difference −11.1%); 84% reached ≥5% vs 16% (Ji 2025).

   Sources

   - Ji et al. (SLIMMER) (2025)

   Updated Nov 2026
3. Day 85–336 · 2.4 mg RCT

   ### The top dose

   You're at 2.4 mg, the highest dose in the obesity trial. That group lost about 13% by week 40 and about 15% by week 48, and was still losing. About two in three lost at least 15%.

   The science

   SLIMMER: 2.4 mg −13.2% at week 40 vs +0.1% (difference −13.3%), 87% ≥5% (Ji 2025). At week 48 (treatment-policy): −15.4% (placebo-adjusted −15.1%), 92.8% ≥5%, 79.6% ≥10%, 63.5% ≥15%, no plateau; liver fat −53.1% at week 40 in those starting at 8% or more (Sciwind, Mar-6-2026).

   Sources

   - Ji et al. (SLIMMER) (2025)
   - Sciwind (approval release) (2026)

   Updated Nov 2026
4. Day 337+ Clinical

   ### A long-term medicine, not a course

   Worth knowing before you stop: with GLP-1 drugs, coming off usually means regaining most of the loss within about a year and a half. Ecnoglutide hasn't been tested in a stopping trial, so this is the pattern of the class. Continue, taper or stop is a call for you and your clinician.

   The science

   A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). A weight-maintenance trial of oral ecnoglutide (NCT07553299) was terminated early in 2026.

   Sources

   - West et al. (2026)

   Updated Nov 2026

Day 1 is the day you start it.

Phase 3 SLIMMER (Ji 2025, Lancet Diabetes Endocrinol), phase 3 in type 2 diabetes (Zhu 2026, Nat Commun; He 2025, Lancet Diabetes Endocrinol), approvals (Shirley 2026, Drugs), Sciwind release Mar-6-2026, interaction studies (Chen 2026; Li 2026). The Chinese label was not read.

Clinical trial data

## More on ecnoglutide

### Dose Guide

- [Ecnoglutide dose guide](https://pepvault.app/lab/dosage/ecnoglutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ecnoglutide-10mg)

### Studies

- [Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis](https://pepvault.app/research/ecnoglutide-kumar-2026)
- [Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1](https://pepvault.app/research/ecnoglutide-eecoh-1-2026)
- [Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutide](https://pepvault.app/research/ecnoglutide-eecoh-2-2025)
- [All 6 studies](https://pepvault.app/research#ecnoglutide)

### Compared with

- [Semaglutide vs Ecnoglutide](https://pepvault.app/peptides/compare/semaglutide-vs-ecnoglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)

## Mixing and a typical run.

Example numbers

### Reconstitution example

Reconstitute a 10 mg vial of Ecnoglutide with 2 mL of bacteriostatic water and a 0.3 mg dose is 6 units on a U-100 syringe, about 33 doses per vial.

- **Vial:** 10 mg
- **Water:** 2 mL
- **Amount:** 0.3 mg

Draw to **6 units**

0.3 mL insulin syringe · 30 units

[Mix it in the Reconstitution Lab](https://pepvault.app/lab) [Open the calculator](https://pepvault.app/tools/reconstitution-calculator)

### Run notes

- **Cycle:** Used continuously, once weekly, in its trials: 40 to 48 weeks in obesity and up to 52 weeks in type 2 diabetes, with the dose doubled every 4 weeks up to the maintenance dose. Community practice — opinions vary. Not a clinical recommendation.
- **Timing:** Once weekly SubQ, same day each week, in its trials. The diabetes trials started at 0.3 mg and doubled every 4 weeks (0.6 mg by week 4, 1.2 mg by week 8); the obesity trial used maintenance doses of 1.2, 1.8 and 2.4 mg. These are trial schedules; the Chinese label governs approved use there.
- **Route:** SubQ injection
- **Stacks:** BPC-157 (GI support)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-next-mixing&mt=8)

<!--/promo-->

## Safety.

### Common side effects

- Decreased appetite
- Diarrhea
- Nausea
- Abdominal bloating
- Weakness

#### Interactions

In interaction studies in healthy people, ecnoglutide did not change warfarin or metformin enough to need a dose change, and its effects on rosuvastatin and digoxin were studied too. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

### Safety notes

In the 40-week SLIMMER phase 3 trial in China, side effects of any kind were reported by 93% on ecnoglutide and 84% on placebo, mostly mild-to-moderate GI events; ten people on ecnoglutide stopped because of side effects. In the diabetes trials, GI side effects came mainly in the step-up period and faded, there was no severe low blood sugar, and pulse rose slightly, as with other GLP-1 drugs; a rise in the lab value lipase was more common than on placebo (about 12% vs 3%), worth knowing if a blood test shows it. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

## Goes with.

- [BPC-157 GI support](https://pepvault.app/peptides/bpc-157)

## One question at a time.

- [Half-life](https://pepvault.app/peptides/ecnoglutide/half-life)
- [Side effects](https://pepvault.app/peptides/ecnoglutide/side-effects)
- [How long it takes to work](https://pepvault.app/peptides/ecnoglutide/how-long-to-work)
- [Legal status](https://pepvault.app/peptides/ecnoglutide/legal-status)

## Compared with.

- [Semaglutide vs Ecnoglutide](https://pepvault.app/peptides/compare/semaglutide-vs-ecnoglutide)

## Mixing charts by vial size.

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ecnoglutide-10mg)

## Studies, in plain English.

- [Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis](https://pepvault.app/research/ecnoglutide-kumar-2026)
- [Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1](https://pepvault.app/research/ecnoglutide-eecoh-1-2026)
- [Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutide](https://pepvault.app/research/ecnoglutide-eecoh-2-2025)
- [Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg arm](https://pepvault.app/research/ecnoglutide-ji-2025)
- [Ecnoglutide: HbA1c fell up to 2.39% at 20 weeks in type 2 diabetes](https://pepvault.app/research/ecnoglutide-zhu-2024)
- [Ecnoglutide: well tolerated weekly for 6 weeks in a phase 1 trial](https://pepvault.app/research/ecnoglutide-guo-2023)
- [Every study on Ecnoglutide](https://pepvault.app/research#ecnoglutide)

## Questions people ask.

### What is Ecnoglutide?

A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". In its phase 3 obesity trial, the 2.4 mg dose took off about 13% at 40 weeks and about 15% at 48 weeks.

### How is Ecnoglutide dosed in research?

The research range for Ecnoglutide is 0.6–2.4 mg, weekly, with a 0.3 mg starting dose. Studied in research — not a recommendation.

### How long does Ecnoglutide last?

The half-life of Ecnoglutide is ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026).

### What do people report on Ecnoglutide?

Commonly reported on Ecnoglutide: appetite control and early GI side effects, much as with semaglutide. It is not FDA-approved.

### Is Ecnoglutide safe?

The research basis for Ecnoglutide is established: clinical trials or FDA-approved use exists. Common side effects in the library: decreased appetite, diarrhea, nausea, abdominal bloating and weakness.

### What does Ecnoglutide stack with?

Common stacks for Ecnoglutide: BPC-157 (GI support).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-next-questions&mt=8)

<!--/promo-->

## Research.

The literature

### Search the latest research

[PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=Ecnoglutide) [Google Scholar](https://scholar.google.com/scholar?q=Ecnoglutide)

## Reference.

- **Cadence:** Weekly
- **Half-life:** ~5.5 days ~5.5 days (measured: 124–138 hours in people, as reported by Sciwind's investigators; Chen 2026)
- **Research basis:** Established Clinical trials or FDA-approved use exists

## More metabolic & glp-1 peptides

- [Efinopegdutide 4–10 mg](https://pepvault.app/peptides/efinopegdutide)
- [5-Amino-1MQ 50–100 mg](https://pepvault.app/peptides/5-amino-1mq)
- [SLU-PP-332 250–1000 mcg](https://pepvault.app/peptides/slu-pp-332)
- [Oxytocin 10–40 IU](https://pepvault.app/peptides/oxytocin)
- [Semaglutide 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)
- [Semaglutide (oral) 1.5–25 mg](https://pepvault.app/peptides/semaglutide-oral)

## Free tools

- [Ecnoglutide dose guide](https://pepvault.app/lab/dosage/ecnoglutide)
- [Reconstitution Lab (3D)](https://pepvault.app/lab)
- [Injection guide (3D)](https://pepvault.app/lab/injection)
- [Peptide Sky (3D)](https://pepvault.app/lab/sky)
- [Peptide tier list](https://pepvault.app/lab/tiers)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

<!--promo-->

PepVault for iPhone

## Track ecnoglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track ecnoglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## More on ecnoglutide

### Dose Guide

- [Ecnoglutide dose guide](https://pepvault.app/lab/dosage/ecnoglutide)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ecnoglutide-10mg)

### Studies

- [Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis](https://pepvault.app/research/ecnoglutide-kumar-2026)
- [Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1](https://pepvault.app/research/ecnoglutide-eecoh-1-2026)
- [Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutide](https://pepvault.app/research/ecnoglutide-eecoh-2-2025)
- [All 6 studies](https://pepvault.app/research#ecnoglutide)

### Compared with

- [Semaglutide vs Ecnoglutide](https://pepvault.app/peptides/compare/semaglutide-vs-ecnoglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Maintenance dose](https://pepvault.app/glossary/maintenance-dose)

<!--promo-->

PepVault for iPhone

## Track ecnoglutide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

Reviewed November 2026 [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
